Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Wulf

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
Blood Advances|August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry studyMaria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
Hemasphere|December 8, 2022
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA TrialFriederike Braulke, Florian Zettl, Marita Ziepert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2021
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)Nicolaus Kröger, Katja Sockel, Christine Wolschke, et al.
Haematologica|March 5, 2026
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenibRadwan Massoud, Sarah Flossdorf, Franziska Hanke, et al.
Frontiers in Immunology|December 31, 2021
<i>HLA-DRB3/4/5</i> Matching Improves Outcome of Unrelated Hematopoietic Stem Cell TransplantationChrysanthi Tsamadou, Daphne Engelhardt, Uwe Platzbecker, et al.
Frontiers in Immunology|August 15, 2020
Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMTAndrzej Frankiewicz, Christophe Peczynski, Sebastian Giebel, et al.
Hemasphere|June 28, 2021
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study GroupCarsten Hirt, Eva Hoster, Michael Unterhalt, et al.
Cancers|August 12, 2022
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective AnalysisEvgenii Shumilov, Lena Aperdannier, Nicole Schmidt, et al.
Bone Marrow Transplantation|November 24, 2022
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experiencePeter Dreger, Udo Holtick, Marion Subklewe, et al.
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Blood Advances|August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry studyMaria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
Hemasphere|December 8, 2022
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA TrialFriederike Braulke, Florian Zettl, Marita Ziepert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2021
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)Nicolaus Kröger, Katja Sockel, Christine Wolschke, et al.
Haematologica|March 5, 2026
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenibRadwan Massoud, Sarah Flossdorf, Franziska Hanke, et al.
Frontiers in Immunology|December 31, 2021
<i>HLA-DRB3/4/5</i> Matching Improves Outcome of Unrelated Hematopoietic Stem Cell TransplantationChrysanthi Tsamadou, Daphne Engelhardt, Uwe Platzbecker, et al.
Frontiers in Immunology|August 15, 2020
Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMTAndrzej Frankiewicz, Christophe Peczynski, Sebastian Giebel, et al.
Hemasphere|June 28, 2021
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study GroupCarsten Hirt, Eva Hoster, Michael Unterhalt, et al.
Cancers|August 12, 2022
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective AnalysisEvgenii Shumilov, Lena Aperdannier, Nicole Schmidt, et al.
Bone Marrow Transplantation|November 24, 2022
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experiencePeter Dreger, Udo Holtick, Marion Subklewe, et al.
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Pageof 14